| D008689 |
Methacrylates |
Acrylic acids or acrylates which are substituted in the C-2 position with a methyl group. |
Methacrylate |
|
| D011464 |
Epoprostenol |
A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). |
Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri |
|
| D002908 |
Chronic Disease |
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). |
Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic |
|
| D006084 |
Graft Rejection |
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. |
Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000179 |
Acrylates |
Derivatives of acrylic acid (the structural formula CH2 |
|
|
| D013930 |
Thromboxane-A Synthase |
An enzyme found predominantly in platelet microsomes. It catalyzes the conversion of PGG(2) and PGH(2) (prostaglandin endoperoxides) to thromboxane A2. EC 5.3.99.5. |
Thromboxane Synthetase,Thromboxane A Synthase,Thromboxane A2 Synthetase,A2 Synthetase, Thromboxane,Synthase, Thromboxane A,Synthase, Thromboxane-A,Synthetase, Thromboxane,Synthetase, Thromboxane A2 |
|
| D013988 |
Ticlopidine |
An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES. |
53-32C,Ticlid,Ticlodix,Ticlodone,Ticlopidine Hydrochloride,53 32C,5332C,Hydrochloride, Ticlopidine |
|
| D013997 |
Time Factors |
Elements of limited time intervals, contributing to particular results or situations. |
Time Series,Factor, Time,Time Factor |
|
| D014652 |
Vascular Diseases |
Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body. |
Disease, Vascular,Diseases, Vascular,Vascular Disease |
|